Whalesbook
The sale of Indian Medicines Pharmaceutical Corporation Limited (IMPCL) to Skymap Pharmaceuticals signals a major shift in India's traditional medicine manufacturing sector.
This divestment concludes a process that began with initial approval in 2017. IMPCL, operated by the Ministry of AYUSH since 1978, will now be run by the Roorkee-based Skymap Pharmaceuticals, which plans to expand its presence in the traditional medicine market.
The sale followed a competitive bidding process that started with seven interested parties, narrowing down to two by early 2026. Skymap Pharmaceuticals' winning bid of approximately ₹121.01 crore surpassed the government's reserve price. This valuation reflects IMPCL's established distribution networks and its role in supplying the National Ayush Mission and numerous Jan Aushadhi Kendras.
Despite the expansion, Skymap Pharmaceuticals faces significant challenges. The company has a substantial debt burden, with reported open charges as high as ₹415 crore, although efforts are underway to clear older bank loans. Skymap must now manage the newly acquired IMPCL alongside its existing operations, a task complicated by recent fluctuations in its profit margins and a reduction in its workforce.
Historically, IMPCL benefited from government-set prices and guaranteed procurement. The transition to private ownership requires a shift to a more competitive pricing strategy to rival other private Ayurvedic companies. While this could spur innovation, Skymap must maintain IMPCL's existing supply chain consistency to avoid losing market share. Success will depend on Skymap's ability to modernize IMPCL's 35-acre Almora facilities without disrupting its established supply routes.